REFERENCES
1. Saito, Y., C. S. Boddupalli, C. Borsotti, and M. G. Manz. 2013.
Dendritic cell homeostasis is maintained by nonhematopoietic and
T-cell-produced Flt3-ligand in steady state and during immune responses.Eur. J. Immunol. 43: 1651–1658.
2. Zhang, S., C. Mantel, and H. E. Broxmeyer. 1999. Flt3 signaling
involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association
with Grb2 and Shc in Baf3/Flt3 cells. J. Leukoc. Biol. 65:
372–380.
3. Sathaliyawala, T., W. E. O’Gorman, M. Greter, M. Bogunovic, V.
Konjufca, Z. E. Hou, G. P. Nolan, M. J. Miller, M. Merad, and B. Reizis.
2010. Mammalian target of rapamycin controls dendritic cell development
downstream of Flt3 ligand signaling. Immunity 33: 597–606.
4. Laouar, Y., T. Welte, X. Y. Fu, and R. A. Flavell. 2003. STAT3 Is
Required for Flt3L-Dependent Dendritic Cell Differentiation.Immunity 19: 903–912.
5. Onai, N., A. Obata-Onai, R. Tussiwand, A. Lanzavecchia, and M. G.
Manz. 2006. Activation of the Flt3 signal transduction cascade rescues
and enhances type I interferon–producing and dendritic cell
development. J. Exp. Med. 203: 227–238.
6. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K.
Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of
functionally mature dendritic cells in Flt3 ligand-treated mice:
multiple dendritic cell subpopulations identified. J. Exp. Med.184: 1953–1962.
7. Waskow, C., K. Liu, G. Darrasse-Jèze, P. Guermonprez, F. Ginhoux, M.
Merad, T. Shengelia, K. Yao, and M. Nussenzweig. 2008. The receptor
tyrosine kinase Flt3 is required for dendritic cell development in
peripheral lymphoid tissues. Nat. Immunol. 9: 676–683.
8. Maraskovsky, E., E. Daro, E. Roux, M. Teepe, C. R. Maliszewski, J.
Hoek, D. Caron, M. E. Lebsack, and H. J. McKenna. 2000. In vivo
generation of human dendritic cell subsets by Flt3 ligand. Blood96: 878–884.
9. Pulendran, B., J. Banchereau, S. Burkeholder, E. Kraus, E. Guinet, C.
Chalouni, D. Caron, C. Maliszewski, J. Davoust, J. Fay, and K. Palucka.
2000. Flt3-Ligand and Granulocyte Colony-Stimulating Factor Mobilize
Distinct Human Dendritic Cell Subsets In Vivo. J. Immunol. 165:
566–572.
10. Mackarehtschian, K., J. D. Hardin, K. A. Moore, S. Boast, S. P.
Goff, and I. R. Lemischka. 1995. Targeted disruption of the flk2/flt3
gene leads to deficiencies in primitive hematopoietic progenitors.Immunity 3: 147–161.
11. McKenna, H. J., K. L. Stocking, R. E. Miller, K. Brasel, T. De
Smedt, E. Maraskovsky, C. R. Maliszewski, D. H. Lynch, J. Smith, B.
Pulendran, E. R. Roux, M. Teepe, S. D. Lyman, and J. J. Peschon. 2000.
Mice lacking flt3 ligand have deficient hematopoiesis affecting
hematopoietic progenitor cells, dendritic cells, and natural killer
cells. Blood 95: 3489–3497.
12. Ginhoux, F., K. Liu, J. Helft, M. Bogunovic, M. Greter, D.
Hashimoto, J. Price, N. Yin, J. Bromberg, S. A. Lira, E. R. Stanley, M.
Nussenzweig, and M. Merad. 2009. The origin and development of
nonlymphoid tissue CD103+ DCs. J. Exp. Med. 206: 3115–3130.
13. Lyman, S. D., M. Seaberg, R. Hanna, J. Zappone, K. Brasel, J. L.
Abkowitz, J. T. Prchal, J. C. Schultz, N. T. Shahidi, S. D. Lyman, M.
Seaberg, R. Hanna, J. Zappone, K. Brasel, J. L. Abkowitz, J. T. Prchal,
J. C. Schultz, N. T. Shahidi, B. S. D. Lyman, M. Seaberg, R. Hanna, J.
Zappone, K. Brasel, J. L. Abkowitz, J. T. Prchal, J. C. Schultz, N. T.
Shahidi, S. D. Lyman, M. Seaberg, R. Hanna, J. Zappone, K. Brasel, J. L.
Abkowitz, J. T. Prchal, J. C. Schultz, and N. T. Shahidi. 1995.
Plasma/Serum Levels of flt3 Ligand Are Low in Normal Individuals and
Highly Elevated in Patients With Fanconi Anemia and Acquired Aplastic
Anemia. Blood 86: 4095–4096.
14. Whartenby, K. A., P. A. Calabresi, E. McCadden, B. Nguyen, D.
Kardian, T. Wang, C. Mosse, D. M. Pardoll, and D. Small. 2005.
Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune
disease. Proc. Natl. Acad. Sci. 102: 16741–16746.
15. Cueto, F. J., C. del Fresno, P. Brandi, A. J. Combes, E.
Hernández-García, A. R. Sánchez-Paulete, M. Enamorado, C. P. Bromley, M.
J. Gomez, R. Conde-Garrosa, S. Mañes, S. Zelenay, I. Melero, S. Iborra,
M. F. Krummel, and D. Sancho. 2021. DNGR-1 limits Flt3L-mediated
antitumor immunity by restraining tumor-infiltrating type I conventional
dendritic cells. J. Immunother. Cancer 9: e002054.
16. Wilson, K. R., J. A. Villadangos, and J. D. Mintern. 2021. Dendritic
cell Flt3 – regulation, roles and repercussions for immunotherapy.Immunol. Cell Biol. imcb.12484.
17. Hayakawa, F., M. Towatari, H. Kiyoi, M. Tanimoto, T. Kitamura, H.
Saito, and T. Naoe. 2000. Tandem-duplicated Flt3 constitutively
activates STAT5 and MAP kinase and introduces autonomous cell growth in
IL-3-dependent cell lines. Oncogene 19: 624–631.
18. Mizuki, M., R. Fenski, H. Halfter, I. Matsumura, R. Schmidt, C.
Muller, W. Gruning, K. Kratz-Albers, S. Serve, C. Steur, T. Buchner, J.
Kienast, Y. Kanakura, W. E. Berdel, H. Serve, C. Müller, W. Grüning, K.
Kratz-Albers, S. Serve, C. Steur, T. Büchner, J. Kienast, Y. Kanakura,
W. E. Berdel, and H. Serve. 2000. Flt3 mutations from patients with
acute myeloid leukemia induce transformation of 32D cells mediated by
the Ras and STAT5 pathways. Blood 96: 3907–3914.
19. Kiyoi, H., R. Ohno, R. Ueda, H. Saito, and T. Naoe. 2002. Mechanism
of constitutive activation of FLT3 with internal tandem duplication in
the juxtamembrane domain. Oncogene 21: 2555–2563.
20. Choudhary, C., J. Schwäble, C. Brandts, L. Tickenbrock, B. Sargin,
T. Kindler, T. Fischer, W. E. Berdel, C. Müller-Tidow, and H. Serve.
2005. AML-associated Flt3 kinase domain mutations show signal
transduction differences compared with Flt3 ITD mutations. Blood106: 265–273.
21. Lee, B. H., Z. Tothova, R. L. Levine, K. Anderson, N. Buza-Vidas, D.
E. E. Cullen, E. P. McDowell, J. Adelsperger, S. Fröhling, B. J. P. P.
Huntly, M. Beran, S. E. Jacobsen, and D. G. Gilliland. 2007. FLT3
Mutations Confer Enhanced Proliferation and Survival Properties to
Multipotent Progenitors in a Murine Model of Chronic Myelomonocytic
Leukemia. Cancer Cell 12: 367–380.
22. Nagel, G., D. Weber, E. Fromm, S. Erhardt, M. Lübbert, W. Fiedler,
T. Kindler, J. Krauter, P. Brossart, A. Kündgen, H. R. Salih, J.
Westermann, G. Wulf, B. Hertenstein, M. Wattad, K. Götze, D. Kraemer, T.
Heinicke, M. Girschikofsky, H. G. Derigs, H. A. Horst, C. Rudolph, M.
Heuser, G. Göhring, V. Teleanu, L. Bullinger, F. Thol, V. I. Gaidzik, P.
Paschka, K. Döhner, A. Ganser, H. Döhner, and R. F. Schlenk. 2017.
Epidemiological, genetic, and clinical characterization by age of newly
diagnosed acute myeloid leukemia based on an academic population-based
registry study (AMLSG BiO). Ann. Hematol. 96: 1993–2003.
23. Yokota, S., H. Kiyoi, M. Nakao, T. Iwai, S. Misawa, T. Okuda, Y.
Sonoda, T. Abe, K. Kahsima, Y. Matsuo, and T. Naoe. 1997. Internal
tandem duplication of the FLT3 gene is preferentially seen in acute
myeloid leukemia and myelodysplastic syndrome among various
hematological malignancies. A study on a large series of patients and
cell lines. Leukemia 11: 1605–1609.
24. Papaemmanuil, E., M. Gerstung, L. Bullinger, V. I. Gaidzik, P.
Paschka, N. D. Roberts, N. E. Potter, M. Heuser, F. Thol, N. Bolli, G.
Gundem, P. Van Loo, I. Martincorena, P. Ganly, L. Mudie, S. McLaren, S.
O’Meara, K. Raine, D. R. Jones, J. W. Teague, A. P. Butler, M. F.
Greaves, A. Ganser, K. Döhner, R. F. Schlenk, H. Döhner, P. J. Campbell,
S. O’Meara, K. Raine, D. R. Jones, J. W. Teague, A. P. Butler, M. F.
Greaves, A. Ganser, K. Döhner, R. F. Schlenk, H. Döhner, and P. J.
Campbell. 2016. Genomic Classification and Prognosis in Acute Myeloid
Leukemia. N. Engl. J. Med. 374: 2209–2221.
25. Lau, C. M., S. A. Nish, N. Yogev, A. Waisman, S. L. Reiner, and B.
Reizis. 2016. Leukemia-associated activating mutation of Flt3 expands
dendritic cells and alters T cell responses. J. Exp. Med. 213:
415–431.
26. Bar-On, L., T. Birnberg, K. L. Lewis, B. T. Edelson, D. Bruder, K.
Hildner, J. Buer, K. M. Murphy, B. Reizis, and S. Jung. 2010. CX3CR1+
CD8 + dendritic cells are a steady-state population related to
plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. 107:
14745–14750.
27. Caminschi, I., D. Vremec, F. Ahmet, M. H. Lahoud, J. A. Villadangos,
K. M. Murphy, W. R. Heath, and K. Shortman. 2012. Antibody responses
initiated by Clec9A-bearing dendritic cells in normal and Batf3-/-mice.Mol. Immunol. 50: 9–17.
28. Villani, A.-C., R. Satija, G. Reynolds, S. Sarkizova, K. Shekhar, J.
Fletcher, M. Griesbeck, A. Butler, S. Zheng, S. Lazo, L. Jardine, D.
Dixon, E. Stephenson, E. Nilsson, I. Grundberg, D. McDonald, A. Filby,
W. Li, P. L. De Jager, O. Rozenblatt-Rosen, A. A. Lane, M. Haniffa, A.
Regev, and N. Hacohen. 2017. Single-cell RNA-seq reveals new types of
human blood dendritic cells, monocytes, and progenitors. Science
(80-. ). 356.
29. See, P., C.-A. Dutertre, J. Chen, P. Günther, N. McGovern, S. E.
Irac, M. Gunawan, M. Beyer, K. Händler, K. Duan, H. R. Bin Sumatoh, N.
Ruffin, M. Jouve, E. Gea-Mallorquí, R. C. M. Hennekam, T. Lim, C. C.
Yip, M. Wen, B. Malleret, I. Low, N. B. Shadan, C. F. S. Fen, A. Tay, J.
Lum, F. Zolezzi, A. Larbi, M. Poidinger, J. K. Y. Chan, Q. Chen, L.
Rénia, M. Haniffa, P. Benaroch, A. Schlitzer, J. L. Schultze, E. W.
Newell, and F. Ginhoux. 2017. Mapping the human DC lineage through the
integration of high-dimensional techniques. Science (80-. ). 356.
30. Leylek, R., M. Alcántara-Hernández, Z. Lanzar, A. Lüdtke, O. A.
Perez, B. Reizis, and J. Idoyaga. 2019. Integrated Cross-Species
Analysis Identifies a Conserved Transitional Dendritic Cell Population.Cell Rep. 29: 3736–3750.e8.
31. Miller, J. C., B. D. Brown, T. Shay, E. L. Gautier, V. Jojic, A.
Cohain, G. Pandey, M. Leboeuf, K. G. Elpek, J. Helft, D. Hashimoto, A.
Chow, J. Price, M. Greter, M. Bogunovic, A. Bellemare-Pelletier, P. S.
Frenette, G. J. Randolph, S. J. Turley, M. Merad, C. Jakubzick, A. J.
Best, J. Knell, A. Goldrath, D. Koller, N. Cohen, P. Brennan, M.
Brenner, A. Regev, A. Fletcher, D. Malhotra, R. Jianu, D. Laidlaw, J.
Collins, K. Narayan, K. Sylvia, J. Kang, R. Gazit, D. J. Rossi, F. Kim,
T. N. Rao, A. Wagers, S. A. Shinton, R. R. Hardy, P. Monach, N. A.
Bezman, J. C. Sun, C. C. Kim, L. L. Lanier, T. Heng, T. Kreslavsky, M.
Painter, J. Ericson, S. Davis, D. Mathis, and C. Benoist. 2012.
Deciphering the transcriptional network of the dendritic cell lineage.Nat. Immunol. 13: 888–899.
32. Teshima, T., P. Reddy, K. P. Lowler, M. A. KuKuruga, C. Liu, K. R.
Cooke, and J. L. M. M. Ferrara. 2002. Flt3 ligand therapy for recipients
of allogeneic bone marrow transplants expands host CD8$α$+ dendritic
cells and reduces experimental acute graft-versus-host disease.Blood 99: 1825–1832.
33. O’Keeffe, M., T. C. Brodnicki, B. Fancke, D. Vremec, G. Morahan, E.
Maraskovsky, R. Steptoe, L. C. Harrison, and K. Shortman. 2005. Fms-like
tyrosine kinase 3 ligand administration overcomes a genetically
determined dendritic cell deficiency in NOD mice and protects against
diabetes development. Int. Immunol. 17: 307–314.
34. Lyman, S. D., L. James, J. Zappone, P. R. Sleath, M. P. Beckmann,
and T. Bird. 1993. Characterization of the protein encoded by the flt3
(flk2) receptor-like tyrosine kinase gene. Oncogene 8: 815–822.
35. Schmidt-Arras, D.-E., A. Böhmer, B. Markova, C. Choudhary, H. Serve,
and F.-D. Böhmer. 2005. Tyrosine Phosphorylation Regulates Maturation of
Receptor Tyrosine Kinases. Mol. Cell. Biol. 25: 3690–3703.
36. Hochrein, H., M. O’Keeffe, T. Luft, S. Vandenabeele, R. J. Grumont,
E. Maraskovsky, and K. Shortman. 2000. Interleukin (IL)-4 is a major
regulatory cytokine governing bioactive IL-12 production by mouse and
human dendritic cells. J. Exp. Med. 192: 823–833.
37. Schnorrer, P., G. M. N. N. N. Behrens, N. S. Wilson, J. L. Pooley,
C. M. Smith, D. El-Sukkari, G. Davey, F. Kupresanin, M. Li, E.
Maraskovsky, G. T. Belz, F. R. Carbone, K. Shortman, W. R. Heath, and J.
A. Villadangos. 2006. The dominant role of CD8+ dendritic cells in
cross-presentation is not dictated by antigen capture. Proc. Natl.
Acad. Sci. U. S. A. 103: 10729–10734.
38. Theisen, D. J., J. T. Davidson, C. G. Briseño, M. Gargaro, E. J.
Lauron, Q. Wang, P. Desai, V. Durai, P. Bagadia, J. R. Brickner, W. L.
Beatty, H. W. Virgin, W. E. Gillanders, N. Mosammaparast, M. S. Diamond,
L. D. Sibley, W. Yokoyama, R. D. Schreiber, T. L. Murphy, and K. M.
Murphy. 2018. WDFY4 is required for cross-presentation in response to
viral and tumor antigens. Science (80-. ). 362: 694–699.
39. Kingston, D., M. A. Schmid, N. Onai, A. Obata-Onai, D. Baumjohann,
M. G. Manz, G. Markus, W. Dc, and M. G. Manz. 2009. The concerted action
of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis.Blood 114: 835–843.
40. Eidenschenk, C., K. Crozat, P. Krebs, R. Arens, D. Popkin, C. N.
Arnold, A. L. Blasius, C. a Benedict, E. M. Y. Moresco, Y. Xia, and B.
Beutler. 2010. Flt3 permits survival during infection by rendering
dendritic cells competent to activate NK cells. Proc. Natl. Acad.
Sci. U. S. A. 107: 9759–9764.
41. Heydt, Q., C. Larrue, E. Saland, S. Bertoli, J. E. Sarry, A. Besson,
S. Manenti, C. Joffre, and V. Mansat-De Mas. 2018. Oncogenic FLT3-ITD
supports autophagy via ATF4 in acute myeloid leukemia. Oncogene37: 787–797.
42. Roche, P. A., and K. Furuta. 2015. The ins and outs of MHC class
II-mediated antigen processing and presentation. Nat. Rev.
Immunol. 15: 203–216.
43. Mintern, J. D., C. Macri, W. J. Chin, S. E. Panozza, E. Segura, N.
L. Patterson, P. Zeller, D. Bourges, S. Bedoui, P. J. Mcmillan, A.
Idris, C. J. Nowell, A. Brown, K. J. Radford, A. P. R. R. Johnston, and
J. A. Villadangos. 2015. Differential use of autophagy by primary
dendritic cells specialized in cross-presentation. Autophagy 11:
906–917.
44. Mintern, J. D., and J. A. Villadangos. 2012. Autophagy and
mechanisms of effective immunity. Front. Immunol. 3: 1–9.
45. Leylek, R., M. Alcántara-Hernández, Z. Lanzar, A. Lüdtke, O. A.
Perez, B. Reizis, and J. Idoyaga. 2019. Integrated Cross-Species
Analysis Identifies a Conserved Transitional Dendritic Cell Population.Cell Rep. 29: 3736-3750.e8.
46. Lahoud, M. H., F. Ahmet, J. G. J.-G. Zhang, S. Meuter, A. N.
Policheni, S. Kitsoulis, C.-N. C. N. Lee, M. O’Keeffe, L. C. Sullivan,
A. G. Brooks, R. Berry, J. Rossjohn, J. D. Mintern, J. Vega-Ramos, J. A.
Villadangos, N. A. Nicola, M. C. Nussenzweig, K. J. Stacey, K. Shortman,
W. R. Heath, and I. Caminschi. 2012. DEC-205 is a cell surface receptor
for CpG oligonucleotides. Proc. Natl. Acad. Sci. 109:
16270–16275.
47. Barnden, M. J., J. Allison, W. R. Heath, and F. R. Carbone. 1998.
Defective TCR expression in transgenic mice constructed using cDNA-
based α- and β-chain genes under the control of heterologous regulatory
elements. Immunol. Cell Biol. 76: 34–40.
48. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J.
Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides
induce positive selection. Cell 76: 17–27.
49. Köntgen, F., G. Süss, C. Stewart, M. Steinmetz, and H. Bluethmann.
1993. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice.Int. Immunol. 5: 957–964.
50. Vremec, D. 2010. The isolation of mouse dendritic cells from
lymphoid tissues and the identification of dendritic cell subtypes by
mutliparameter flow cytometry. Methods Mol. Biol. 595: 205–209.